XML 58 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments (Tables)
 12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Summary of Cash, Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:
As of December 31, 2021As of December 31, 2020
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(in millions)
Cash equivalents:
Money market funds
$3,478.1 $— $— $3,478.1 $3,141.1 $— $— $3,141.1 
Marketable securities:
U.S. Treasury securities$86.6 $— $(0.2)$86.4 $— $— $— $— 
Government-sponsored enterprise securities
69.0 — — 69.0 80.0 — — 80.0 
Corporate debt securities
91.1 — (0.2)90.9 231.3 0.4 (0.1)231.6 
Commercial paper
252.8 — (0.1)252.7 163.3 — — 163.3 
Total marketable debt securities499.5 — (0.5)499.0 474.6 0.4 (0.1)474.9 
Corporate equity securities
69.4 167.1 (5.6)230.9 51.4 144.4 — 195.8 
Total marketable securities$568.9 $167.1 $(6.1)$729.9 $526.0 $144.8 $(0.1)$670.7 
Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:
December 31,
20212020
(in millions)
Cash and cash equivalents$3,478.1 $3,141.1 
Marketable securities
499.0 474.9 
Total
$3,977.1 $3,616.0 
Available-for-sale debt securities by contractual maturity were as follows:
December 31,
20212020
(in millions)
Matures within one year$3,912.3 $3,526.2 
Matures after one year through five years
64.8 89.8 
Total
$3,977.1 $3,616.0 
Schedule of Company’s Net Unrealized Gains on Corporate Equity Securities During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:
202120202019
(in millions)
Net unrealized gains$17.1 $136.2 $143.2 
Schedule of Sale of Equity Investments
During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:
20202019
(in millions)
Proceeds received$437.6 $94.9 
Weighted-average cost basis$103.3 $29.8